Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Maze Therapeutics will present data on MZE829 and MZE782 at ASN Kidney Week, held October 21-25, 2026 in Denver. The oral presentation covers previously reported Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, updated with additional details; two posters will cover preclinical research supporting SLC6A19 inhibition (MZE782's mechanism) in chronic kidney disease. No new data is being announced; the release is a visibility event ahead of the October 24 oral presentation led by Duke's Dr.
Key figures
- Drug Name
- MZE829
- Phase Of Trial
- Phase 2
- Additional pipeline asset
- MZE782 (SLC6A19 inhibitor, Phase 2)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.